It’s little surprise that Tim is ranked in the Legal 500 as a ‘next generation’ pharma and biotech lawyer. With a long-held interest in the field, allied to scientific training, he is a firm believer in the transformative power of life sciences and the remarkable impact they can have on people’s lives.
Today, his principal focus is on patents and related rights, providing strategic advice and litigation expertise in the English Courts to innovator biotech and pharma companies. In helping his clients enforce, defend and understand their IP rights and minimise their risks, Tim has advised on numerous blockbuster pharmaceutical and biotech treatments, including various monoclonal antibody therapies.
The approach he takes to this work is always collaborative - he often works as part of a multi-jurisdictional team and relishes the challenge of forming and deploying creative legal and commercial strategies.
Tim is equally active in supporting the next generation of leaders in life sciences and healthcare. He enjoys regular lecturing and teaching, and working with entrepreneurs, start-ups and spin-outs, helping them understand how to use IP to protect their innovations.
Highly regarded in the wider industry, Tim is a member of the European Patent Lawyers Association (EPLAW) and Co-chair of the Biotech litigation subcommittee of the American Intellectual Property Lawyers Association (AIPLA), and teaches on Oxford University's Postgraduate Intellectual Property Diploma.
Insights
Patents Court offers guidance on use of doctrine of equivalents
Decision makes it clear that a patentee must consider their infringement position at an early stage in proceedings
Can gene-editing help solve the energy crisis?
What role can biofuels play in fighting climate change and can CRISPR sequencing technology help it reach its potential?
Battery technology advances are powering the rapid rise of electric vehicles
Patents filed, research and investment are undergoing sustained growth, which is reducing costs in an increasingly mature market
'Crown use' defence in patent infringement claims hinges on authorisation
Appellate-level analysis of rarely used defence limits up-front protection for suppliers of goods and services to government
Judicial changes strengthen English Patents Court
Recent high-profile appointments and developments will bolster the UK's reputation as a forum for litigating complex patent disputes
A new bag of tricks? Obvious if it could have been done before (says the Patents Court)
In order to establish obviousness for the purposes of a patent application, it is enough to show that the idea...
Illuminating insufficiency: the English Patents Court examines "Regeneron ranges"
In applying the insufficiency principles laid down in Regeneron, the High Court highlights some key considerations for patentees looking to...